Evaluation of ENPP1 Expression and Immune Response in Bladder Cancer Patients

CompletedOBSERVATIONAL
Enrollment

12

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

October 1, 2024

Study Completion Date

October 20, 2024

Conditions
Bladder (Urothelial, Transitional Cell) Cancer
Interventions
DIAGNOSTIC_TEST

Immunohistochemistry

This intervention will specifically focus on evaluating the role of ENPP1 in bladder cancer patients, distinguishing it from other interventions by targeting immune evasion and chemoresistance pathways. The intervention will include a combination of targeted molecular therapies and immunotherapy, aimed at assessing the therapeutic potential of ENPP1 inhibition in improving treatment outcomes for bladder cancer patients. This differs from previous studies by integrating advanced biomarker analysis and personalized treatment approaches based on ENPP1 expression levels.

Trial Locations (1)

730000

Lanzhou University Second Hospital, Lanzhou

All Listed Sponsors
lead

Lanzhou University Second Hospital

OTHER

NCT06657755 - Evaluation of ENPP1 Expression and Immune Response in Bladder Cancer Patients | Biotech Hunter | Biotech Hunter